MET and lung adenocarcinoma: MET amplification is an independent poor prognostic factor,6,11,12,13,14 which defines an aggressive, treatment-resistant malignancy with a very short median overall survival (OS) of 4 months6,9 Despite expression (≥1%) of programmed death-ligand 1 (PD-L1) in 85% of lung adenocarcinomas with MET amplification,15 outcomes with immunotherapies are poor.9